mitomycin has been researched along with Anemia in 15 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 9.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 9.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer." | 9.07 | Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994) |
| "Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy." | 6.76 | Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy. ( Cartei, F; Cartei, G; Colombrino, E; Fiorica, F; Giraldi, T; Micucci, M; Plebani, M; Sanzari, MC; Zustovich, F, 2011) |
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 5.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 5.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer." | 5.07 | Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994) |
| "A comparison of patients receiving combination chemotherapy with mitomycin C, mitozantrone and methotrexate (3M) with and without tamoxifen for treatment of primary breast cancer indicates an increased risk of anaemia (P < 0." | 5.07 | A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. ( Ashley, SE; Luckit, J; Montes, A; O'Brien, ME; Powles, TJ; Treleaven, J, 1993) |
| "Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use." | 2.80 | Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. ( Amitay, Y; Berger, R; Gabizon, AA; Golan, T; Grenader, T; La-Beck, NM; Ohana, P; Shmeeda, H; Tahover, E, 2015) |
| "Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy." | 2.76 | Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy. ( Cartei, F; Cartei, G; Colombrino, E; Fiorica, F; Giraldi, T; Micucci, M; Plebani, M; Sanzari, MC; Zustovich, F, 2011) |
| " Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| "We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy." | 1.35 | Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. ( Aydogan, B; Chmura, SJ; Devisetty, K; Jani, AB; Kindler, HL; Mell, LK; Miller, RC; Mundt, AJ; Roeske, JC; Salama, JK; Schomas, DA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Golan, T | 1 |
| Grenader, T | 1 |
| Ohana, P | 1 |
| Amitay, Y | 1 |
| Shmeeda, H | 1 |
| La-Beck, NM | 1 |
| Tahover, E | 1 |
| Berger, R | 1 |
| Gabizon, AA | 1 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 2 |
| Kripp, M | 2 |
| Lukan, N | 2 |
| Merx, K | 2 |
| Hofmann, WK | 1 |
| Hochhaus, A | 2 |
| Hofheinz, RD | 2 |
| Cartei, G | 1 |
| Colombrino, E | 1 |
| Sanzari, MC | 1 |
| Plebani, M | 1 |
| Micucci, M | 1 |
| Fiorica, F | 1 |
| Giraldi, T | 1 |
| Zustovich, F | 1 |
| Cartei, F | 1 |
| Lim, KH | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| KUBOTA, J | 1 |
| OBARA, T | 1 |
| KADONO, T | 1 |
| Hai-Yang, G | 1 |
| Ping, S | 1 |
| Li, JI | 1 |
| Chang-Hong, X | 1 |
| Fu, T | 1 |
| Mell, LK | 1 |
| Schomas, DA | 1 |
| Salama, JK | 1 |
| Devisetty, K | 1 |
| Aydogan, B | 1 |
| Miller, RC | 1 |
| Jani, AB | 1 |
| Kindler, HL | 1 |
| Mundt, AJ | 1 |
| Roeske, JC | 1 |
| Chmura, SJ | 1 |
| Gnad-Vogt, U | 1 |
| Schultheis, B | 1 |
| Pacini, P | 1 |
| Tucci, E | 1 |
| Algeri, R | 1 |
| Rinaldini, M | 1 |
| Guarnieri, A | 1 |
| Valzelli, S | 1 |
| Neri, B | 1 |
| Steinlein, P | 1 |
| Deiner, E | 1 |
| Leutz, A | 1 |
| Beug, H | 1 |
| Montes, A | 1 |
| Powles, TJ | 1 |
| O'Brien, ME | 1 |
| Ashley, SE | 1 |
| Luckit, J | 1 |
| Treleaven, J | 1 |
| Hartmann, JT | 1 |
| Harstrick, A | 1 |
| Daikeler, T | 1 |
| Kollmannsberger, C | 1 |
| Müller, C | 1 |
| Seeber, S | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Kunikane, H | 1 |
| Watanabe, K | 1 |
| Fukuoka, M | 1 |
| Saijo, N | 1 |
| Furuse, K | 1 |
| Ikegami, H | 1 |
| Ariyoshi, Y | 1 |
| Kishimoto, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Phase 1B Study for Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Oxaliplatin-based Chemotherapy in Patients With Gastro-intestinal Malignancies[NCT04729205] | Phase 1 | 9 participants (Actual) | Interventional | 2021-01-13 | Terminated (stopped due to Investigational drug not available) | ||
| A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.[NCT01705002] | Phase 1 | 88 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for mitomycin and Anemia
| Article | Year |
|---|---|
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Chemoradiotherapy; Chronic Disease; D | 2011 |
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Diseas | 2012 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administ | 1994 |
A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interact | 1993 |
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Colorectal Neoplasms; Diarrhea; Disease Progressio | 1998 |
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carcinoma, Non-Small-Cell | 2001 |
6 other studies available for mitomycin and Anemia
| Article | Year |
|---|---|
[TREATMENTS OF LEUKOPENIA ASSOCIATED WITH THE THERAPY OF MALIGNANT TUMORS].
Topics: Anemia; Anemia, Aplastic; Antineoplastic Agents; Bone Marrow Transplantation; Japan; Leukocyte Count | 1963 |
[MICROCHEMICAL STUDY OF VARIOUS CELLS USING THE MICROSPECTROPHOTOMETER. II. ON THE RELATIVE AMOUNT OF DNA IN THE BONE MARROW CELLS].
Topics: Adenine; Anemia; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; DNA; Microchemistry; Mitomyc | 1963 |
[STUDIES ON THE EFFECTS OF MITOMYCIN C AGAINST PATIENTS WITH MALIGNANT TUMORS, PARTICULARLY ON THE CHANGES OF SERUM IRON, SERUM COPPER AND IRON BINDING CAPACITY. I. EFFECTS OF MITOMYCIN C AGAINST NORMAL DOGS].
Topics: Agranulocytosis; Anemia; Animals; Blood Chemical Analysis; Blood Platelets; Blood Protein Electropho | 1964 |
Therapeutic effects of Lycium barbarum polysaccharide (LBP) on mitomycin C (MMC)-induced myelosuppressive mice.
Topics: Anemia; Animals; Antibiotics, Antineoplastic; Female; Hematocrit; Injections, Intravenous; Injection | 2004 |
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplas | 2008 |
Recombinant murine erythropoietin receptor expressed in avian erythroid progenitors mediates terminal erythroid differentiation in vitro.
Topics: Anemia; Animals; Bone Marrow Cells; Cell Differentiation; Cell Line, Transformed; Cells, Cultured; C | 1994 |